• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可切除的大细胞神经内分泌癌与小细胞肺癌基于临床病理数据的生物学行为差异。

The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.

机构信息

Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

出版信息

Clin Lung Cancer. 2013 Sep;14(5):535-40. doi: 10.1016/j.cllc.2013.04.003. Epub 2013 Jun 20.

DOI:10.1016/j.cllc.2013.04.003
PMID:23792008
Abstract

INTRODUCTION

Large cell neuroendocrine carcinoma of the lung and SCLC are collectively classified as high-grade NECs. However, there have been few reports focusing on the differences of clinicopathological prognostic factors between resectable LCNEC and SCLC.

PATIENTS AND METHODS

We reviewed the clinical data of 140 patients who underwent complete resection of high grade NEC in our institute and analyzed the clinicopathological features in relation to their survival.

RESULTS

There were no statistically significant differences in overall and recurrence-free survival between pure and combined subtypes in either LCNEC or SCLC. In LCNEC, larger tumor diameter (P = .01), nodal metastasis (P < .01), lymphatic permeation (P < .01), and vascular invasion (P = .01) were unfavorable prognostic factors. However, in SCLC, tumor diameter and vascular invasion were not prognostic factors, but nodal metastasis (P < .01) and lymphatic permeation (P = .03) were strongly correlated with poor prognosis.

CONCLUSION

There were no apparent differences in biological behavior between pure and combined subtypes in either LCNEC or SCLC. Lymphatic involvement was an important unfavorable prognostic factor in SCLC, whereas tumor diameter, vascular invasion, and lymphatic involvement had a poor prognostic effect in LCNEC.

摘要

简介

肺大细胞神经内分泌癌和小细胞肺癌统称为高级别神经内分泌癌。然而,目前鲜有报道聚焦于可切除的大细胞神经内分泌癌和小细胞肺癌之间临床病理预后因素的差异。

患者与方法

我们回顾了我院 140 例接受高级别神经内分泌癌完全切除术患者的临床资料,并分析了与生存相关的临床病理特征。

结果

无论是在大细胞神经内分泌癌还是小细胞肺癌中,单纯型和混合型亚组之间的总生存率和无复发生存率均无统计学差异。在大细胞神经内分泌癌中,肿瘤直径较大(P =.01)、淋巴结转移(P <.01)、淋巴渗透(P <.01)和血管浸润(P =.01)是不良预后因素。然而,在小细胞肺癌中,肿瘤直径和血管浸润不是预后因素,但淋巴结转移(P <.01)和淋巴渗透(P =.03)与不良预后密切相关。

结论

在大细胞神经内分泌癌或小细胞肺癌中,单纯型和混合型亚组之间的生物学行为没有明显差异。淋巴浸润是小细胞肺癌的一个重要不良预后因素,而肿瘤直径、血管浸润和淋巴浸润对大细胞神经内分泌癌的预后有不良影响。

相似文献

1
The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.可切除的大细胞神经内分泌癌与小细胞肺癌基于临床病理数据的生物学行为差异。
Clin Lung Cancer. 2013 Sep;14(5):535-40. doi: 10.1016/j.cllc.2013.04.003. Epub 2013 Jun 20.
2
A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.肺外周、小细胞型高级神经内分泌肿瘤的临床病理研究:小细胞肺癌与大细胞神经内分泌癌的区别。
Eur J Cardiothorac Surg. 2012 Apr;41(4):841-6. doi: 10.1093/ejcts/ezr132. Epub 2011 Dec 21.
3
Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.癌症干细胞样标志物在肺高级别神经内分泌癌中的临床病理意义
J Cancer Res Clin Oncol. 2015 Dec;141(12):2121-30. doi: 10.1007/s00432-015-1985-3. Epub 2015 May 12.
4
Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.经活检诊断的不可切除高级别肺神经内分泌癌的临床特征。
Lung Cancer. 2012 Mar;75(3):368-73. doi: 10.1016/j.lungcan.2011.08.012. Epub 2011 Sep 13.
5
High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.肺高级别神经内分泌癌:大细胞神经内分泌癌与小细胞肺癌的临床病理对照研究
Pathol Int. 2009 Aug;59(8):522-9. doi: 10.1111/j.1440-1827.2009.02402.x.
6
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.纯型和混合型肺大细胞神经内分泌癌患者临床结局的差异:一项多中心回顾性研究。
Lung Cancer. 2020 Jan;139:118-123. doi: 10.1016/j.lungcan.2019.11.004. Epub 2019 Nov 11.
7
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.含伊立替康和顺铂的联合化疗治疗肺大细胞神经内分泌癌:一项多中心 II 期研究。
J Thorac Oncol. 2013 Jul;8(7):980-4. doi: 10.1097/JTO.0b013e31828f6989.
8
Stress protein Hsp27 expression predicts the outcome in operated small cell lung carcinoma and large cell neuroendocrine carcinoma patients.应激蛋白Hsp27的表达可预测接受手术治疗的小细胞肺癌和大细胞神经内分泌癌患者的预后。
J BUON. 2013 Oct-Dec;18(4):915-20.
9
Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?大细胞神经内分泌肺癌应归类为小细胞肺癌还是与其他大细胞癌一起治疗?
J Thorac Oncol. 2011 Jun;6(6):1050-8. doi: 10.1097/JTO.0b013e318217b6f8.
10
Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung.肺大细胞神经内分泌癌患者术后生存的预测因素。
Ann Thorac Surg. 2015 Mar;99(3):983-9. doi: 10.1016/j.athoracsur.2014.10.015. Epub 2015 Jan 14.

引用本文的文献

1
Comparison of clinicopathologic features and prognosis between surgically resected pulmonary large-cell neuroendocrine carcinoma and small-cell lung cancer.手术切除的肺大细胞神经内分泌癌与小细胞肺癌的临床病理特征及预后比较
J Thorac Dis. 2025 Apr 30;17(4):2394-2410. doi: 10.21037/jtd-2025-345. Epub 2025 Apr 27.
2
Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis.在IV期肺大细胞神经内分泌癌中添加免疫检查点抑制剂增强化疗疗效:一项真实世界分析
J Cancer. 2023 Sep 25;14(17):3169-3175. doi: 10.7150/jca.87052. eCollection 2023.
3
Differences between Advanced Large Cell Neuroendocrine Carcinoma and Advanced Small Cell Lung Cancer: A Propensity Score Matching Analysis.
晚期大细胞神经内分泌癌与晚期小细胞肺癌的差异:一项倾向评分匹配分析
J Cancer. 2023 May 21;14(9):1541-1552. doi: 10.7150/jca.84600. eCollection 2023.
4
Role of surgery in high-grade neuroendocrine tumors of the lung.手术在肺高级别神经内分泌肿瘤中的作用。
Turk Gogus Kalp Damar Cerrahisi Derg. 2022 Jul 29;30(3):389-394. doi: 10.5606/tgkdc.dergisi.2022.19700. eCollection 2022 Jul.
5
Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large cell neuroendocrine carcinoma.不典型类癌、具有不典型类癌形态和核分裂象增多的神经内分泌肿瘤、大细胞神经内分泌癌的临床和遗传学相似性评估。
BMC Cancer. 2022 Mar 24;22(1):321. doi: 10.1186/s12885-022-09391-w.
6
Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung.手术切除的肺高级别神经内分泌肿瘤中肺大细胞神经内分泌癌与小细胞癌合并的比较研究
Front Oncol. 2021 Sep 22;11:714549. doi: 10.3389/fonc.2021.714549. eCollection 2021.
7
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.免疫检查点抑制剂在肺大细胞神经内分泌肿瘤中的真实世界生存结果。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001999.
8
Impact of treatment modality on long-term survival of stage IA small-cell lung cancer patients: a cohort study of the U.S. SEER database.治疗方式对IA期小细胞肺癌患者长期生存的影响:一项基于美国监测、流行病学和最终结果(SEER)数据库的队列研究
Ann Transl Med. 2020 Oct;8(20):1292. doi: 10.21037/atm-20-5525.
9
Clinicopathological Factors Related to Recurrence Patterns of Resected Non-Small Cell Lung Cancer.与切除的非小细胞肺癌复发模式相关的临床病理因素
J Clin Med. 2020 Aug 1;9(8):2473. doi: 10.3390/jcm9082473.
10
Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection.接受手术治疗的临床I-IIIA期大细胞神经内分泌肺癌患者的治疗结果
J Clin Med. 2020 May 7;9(5):1370. doi: 10.3390/jcm9051370.